Table 5.
Secondary cardiovascular preventive medication by treatment group
| Baseline | 6 months follow-up | 12 months follow-up | 6 months | 12 months | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nurse group | Usual care | Nurse group | Usual care | Nurse group | Usual care | p Value | p Value | |||||||
| (n=366) | (n=367) | (n=358) | (n=352) | (n=355) | (n=348) | |||||||||
| Any antithrombotic agent*, n (%) | 363 | (99%) | 363 | (99%) | 354 | (99%) | 354 | (99%) | 348 | (98%) | 342 | (98%) | 0.99 | 0.99 |
| Any lipid lowering agent†, n (%) | 350 | (96%) | 352 | (96%) | 345 | (96%) | 337 | (96%) | 331 | (93%) | 328 | (94%) | 0.70 | 0.64 |
| β Blockers, n (%) | 328 | (90%) | 326 | (89%) | 296 | (83%) | 285 | (81%) | 270 | (76%) | 272 | (78%) | 0.56 | 0.53 |
| Calcium channel blocker, n (%) | 65 | (18%) | 65 | (18%) | 82 | (23%) | 58 | (17%) | 77 | (22%) | 65 | (19%) | 0.04 | 0.35 |
| Diuretics, n (%) | 52 | (14%) | 52 | (15%) | 74 | (21%) | 53 | (15%) | 76 | (21%) | 53 | (15%) | 0.06 | 0.04 |
| ACE inhibitors, n (%) | 200 | (55%) | 175 | (48%) | 209 | (58%) | 162 | (46%) | 201 | (57%) | 160 | (46%) | 0.001 | 0.005 |
| Angiotensin II receptor blockers, n (%) | 36 | (10%) | 32 | (9%) | 56 | (16%) | 49 | (14%) | 58 | (16%) | 55 | (16%) | 0.53 | 0.92 |
| α Blockers, n (%) | 0 | (0%) | 3 | (1%) | 0 | (0%) | 4 | (1%) | 0 | (0%) | 4 | (1%) | 0.06 | 0.06 |
Data are n (%).
*Antithrombotic agents are aspirine, clopidogrel, dipyridamol or any oral anticoagulant.
†Lipid lowering agents are statins or non-statin lipid lowering agents.